Cited by 121

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Toll-like receptor 4: A potential therapeutic target for multiple human diseases

Wei, Jinrui, Zhang, Yan, Li, Haopeng, Wang, Fuquan, Yao, Shanglong·2023·Biomedicine & Pharmacotherapy

Abstract

The immune response plays a pivotal role in the pathogenesis of diseases. Toll-like receptor 4 (TLR4), as an intrinsic immune receptor, exhibits widespread in vivo expression and its dysregulation significantly contributes to the onset of various diseases, encompassing cardiovascular disorders, neoplastic conditions, and inflammatory ailments. This comprehensive review centers on elucidating the architectural and distributive characteristics of TLR4, its conventional signaling pathways, and its mode of action in diverse disease contexts. Ultimately, this review aims to propose novel avenues and therapeutic targets for clinical intervention.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.biopha.2023.115338

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 9 references

Research works printed but not linked: 110

  1. Płóciennikowska, 2015, Co-operation of TLR4 and raft proteins in LPS-induced pro-inflammatory signaling, Cell Mol. Life Sci., 72, 557, 10.1007/s00018-014-1762-5 · DOI
  2. Rocha, 2016, Saturated fatty acids trigger TLR4-mediated inflammatory response, Atherosclerosis, 244, 211, 10.1016/j.atherosclerosis.2015.11.015 · DOI · Paper page
  3. Zhang, 2022, Toll-like receptor 4 (TLR4) inhibitors: current research and prospective, Eur. J. Med Chem., 235, 10.1016/j.ejmech.2022.114291 · DOI
  4. Firmal, 2020, Insight into TLR4-mediated immunomodulation in normal pregnancy and related disorders, Front Immunol., 11, 10.3389/fimmu.2020.00807 · DOI
  5. McGettrick, 2007, Toll-like receptors: key activators of leucocytes and regulator of haematopoiesis, Br. J. Haematol., 139, 185, 10.1111/j.1365-2141.2007.06802.x · DOI
  6. Khanmohammadi, 2021, Role of Toll-like receptors in the pathogenesis of COVID-19, J. Med Virol., 93, 2735, 10.1002/jmv.26826 · DOI
  7. Krüger, 2017, Quantitative single-molecule imaging of TLR4 reveals lig-and-specific receptor dimerization., Sci. Signal, 10, 10.1126/scisignal.aan1308 · DOI
  8. Jiang, 2005, CD14 is required for MyD88-independent LPS signaling, Nat. Immunol., 6, 565, 10.1038/ni1207 · DOI
  9. Bruno, 2018, Targeting toll-like receptor-4 (TLR4)-an emerging therapeutic target for persistent pain states, Pain, 159, 1908, 10.1097/j.pain.0000000000001306 · DOI
  10. Tsuchiya, 2015, Activation of MEK/ERK pathways through NF-κB ac-tivation is involved in interleukin-1β-induced cyclooxygenease-2 expression in canine dermal fibroblasts., Vet. Immunol. Immunopathol., 168, 223, 10.1016/j.vetimm.2015.10.003 · DOI
  11. Moghimpour Bijani, 2012, Toll-like receptor signaling pathways in cardiovascular diseases: challenges and opportunities, Int Rev. Immunol., 31, 379, 10.3109/08830185.2012.706761 · DOI
  12. Mohyuddin, 2021, Effect of chitosan on blood profile, inflammatory cytokines by activating TLR4/NF-κB signaling pathway in intestine of heat stressed mice, Sci. Rep., 11, 10.1038/s41598-021-98931-8 · DOI
  13. Yu, 2018, Calpain inhibitor I attenuates atherosclerosis and inflammation in atheroscle-rotic rats through eNOS/NO/NF-κB pathway., Can. J. Physiol. Pharm., 96, 60, 10.1139/cjpp-2016-0652 · DOI
  14. Cheng, 2016, Extractable and non-extractable polyphenols from blueberries modulate LPS-induced expression of iNOS and COX-2 in RAW264.7 macrophages via the NF-κB signalling pathway, J. Sci. Food Agric., 96, 3393, 10.1002/jsfa.7519 · DOI
  15. Funami, 2017, Functional interfaces between TICAM-2/TRAM and TI-CAM-1/TRIF in TLR4 signaling., Biochem Soc. Trans., 45, 929, 10.1042/BST20160259 · DOI
  16. Marongiu, 2019, Below the surface: The inner lives of TLR4 and TLR9, J. Leukoc. Biol., 106, 147, 10.1002/JLB.3MIR1218-483RR · DOI
  17. Ullah, 2016, TRIF-dependent TLR signaling, its functions in host defense and inflam-mation, and its potential as a therapeutic target., J. Leukoc. Biol., 100, 27, 10.1189/jlb.2RI1115-531R · DOI
  18. Lukhele, 2019, Type I interferon signaling, regulation and gene stimulation in chronic virus infec-tion., Semin Immunol., 43, 10.1016/j.smim.2019.05.001 · DOI
  19. Cusson-Hermance, 2005, Rip1 mediates the Trif-dependent toll-like receptor 3- and 4-induced NF-{kappa}B activation but does not contribute to interferon regulatory factor 3 activation, J. Biol. Chem., 280, 36560, 10.1074/jbc.M506831200 · DOI
  20. Sato, 2003, J. Immunol., 171, 4304, 10.4049/jimmunol.171.8.4304 · DOI
  21. Wolf, 2019, Immunity and Inflammation in Atherosclerosis, Circ. Res, 124, 315, 10.1161/CIRCRESAHA.118.313591 · DOI
  22. Childs, 2016, Senescent intimal foam cells are deleterious at all stages of atherosclerosis, Science, 354, 472, 10.1126/science.aaf6659 · DOI · Paper page
  23. Stary, 1994, A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association, Circulation, 89, 2462, 10.1161/01.CIR.89.5.2462 · DOI
  24. Liu, 2018, Myeloid-specific deletion of peptidylarginine deiminase 4 mitigates atherosclerosis, Front Immunol., 9, 10.3389/fimmu.2018.01680 · DOI
  25. Yang, 2021, Neutrophil elastase promotes neointimal hyperplasia by targeting toll-like receptor 4 (TLR4)-NF-κB signalling, Br. J. Pharm., 178, 4048, 10.1111/bph.15583 · DOI
  26. Tsourouktsoglou, 2020, Histones, DNA, and citrullina-tion promote neutrophil extracellular trap inflammation by regulating the localization and activation of TLR4, Cell Rep., 31, 10.1016/j.celrep.2020.107602 · DOI
  27. Durham, 2018, Role of smooth muscle cells in vascular calcification: im-plications in atherosclerosis and arterial stiffness, Cardiovasc Res, 114, 590, 10.1093/cvr/cvy010 · DOI
  28. Zhai, 2022, Extracel-lular traps from activated vascular smooth muscle cells drive the progression of atherosclerosis., Nat. Commun., 13, 10.1038/s41467-022-35330-1 · DOI
  29. Wu, 2020, Breaking the vicious loop between inflammation, oxidative stress and coagulation, a novel anti-thrombus insight of nattokinase by inhibiting LPS-induced inflammation and oxidative stress, Redox Biol., 32, 10.1016/j.redox.2020.101500 · DOI
  30. Jackson, 2019, Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms, Blood, 133, 906, 10.1182/blood-2018-11-882993 · DOI
  31. Levi, 2004, Bidirectional relation between inflammation and coagulation, Circulation, 109, 2698, 10.1161/01.CIR.0000131660.51520.9A · DOI
  32. Szaba, 2002, Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo, Blood, 99, 1053, 10.1182/blood.V99.3.1053 · DOI
  33. Di Lorenzo, 2015, Activation of human Toll-like receptor 4 (TLR4)·myeloid dif-ferentiation factor 2 (MD-2) by hypoacylated lipopolysaccharide from a clinical isolate of Burkholderia cenocepacia, J. Biol. Chem., 290, 21305, 10.1074/jbc.M115.649087 · DOI
  34. Kawai, 2005, Toll-like receptor downstream signaling, Arthritis Res Ther., 7, 12, 10.1186/ar1469 · DOI
  35. Yu, 2008, Phosphoryla-tion of Thr-178 and Thr-184 in the TAK1 T-loop is required for interleukin (IL)-1-mediated optimal NFkappaB and AP-1 ac-tivation as well as IL-6 gene expression, J. Biol. Chem., 283, 24497, 10.1074/jbc.M802825200 · DOI
  36. Smiley, 2001, Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4, J. Immunol., 167, 2887, 10.4049/jimmunol.167.5.2887 · DOI
  37. Hua, 2011, Plasminogen activator inhibitor type-1 deficiency exaggerates LPS-induced acute lung injury through enhancing Toll-like receptor 4 signaling pathway, Blood Coagul. Fibrinolysis, 22, 480, 10.1097/MBC.0b013e328346ef56 · DOI
  38. Ren, 2015, Plasminogen activator inhibitor-1 regulates LPS-induced TLR4/MD-2 pathway activation and inflammation in alveolar macrophages, Inflammation, 38, 384, 10.1007/s10753-014-0042-8 · DOI
  39. Dörge, 2000, Perfusion-contraction mismatch with coronary microvascular obstruction: role of inflammation, Am. J. Physiol. Heart Circ. Physiol., 279, H2587, 10.1152/ajpheart.2000.279.6.H2587 · DOI
  40. Huang, 2016, Exogenous hydrogen sulfide attenuates high glu-cose-induced cardiotoxicity by inhibiting NLRP3 inflammasome activation by suppressing TLR4/NF-κB pathway in H9c2 cells, Cell Physiol. Biochem, 40, 1578, 10.1159/000453208 · DOI
  41. Su, 2018, Effects of the TLR4/Myd88/NF-κB signaling pathway on NLRP3 inflammasome in coronary microembolization-induced myocardial injury, Cell Physiol. Biochem, 47, 1497, 10.1159/000490866 · DOI
  42. Wang, 2017, TAK-242 protects against apoptosis in coronary microemboliza-tion-induced myocardial injury in rats by suppressing TLR4/NF-κB signaling pathway, Cell Physiol. Biochem, 41, 1675, 10.1159/000471248 · DOI
  43. Fan, 2019, Qi-Li-Qiang-Xin alleviates isoproterenol-induced myocardial injury by inhibiting excessive autophagy via activating AKT/mTOR pathway, Front Pharm., 10, 10.3389/fphar.2019.01329 · DOI
  44. Liu, 2018, Curcumin alleviates isoproterenol-induced cardiac hypertrophy and fi-brosis through inhibition of autophagy and activation of mTOR, Eur. Rev. Med Pharm. Sci., 22, 7500
  45. Thangaiyan, 2018, Preventive effect of apigenin against isopro-terenol-induced apoptosis in cardiomyoblasts., J. Biochem Mol. Toxicol., 32, 10.1002/jbt.22213 · DOI
  46. Kumari, 2020, Musa balbisiana fruit rich in polyphenols attenuates isoproterenol-induced cardiac hypertrophy in rats via inhibition of inflammation and oxidative stress, Oxid. Med Cell Longev., 2020, 10.1155/2020/7147498 · DOI
  47. Liao, 2022, Main active components of Si-Miao-Yong-An decoction (SMYAD) attenuate autophagy and apoptosis via the PDE5A-AKT and TLR4-NOX4 pathways in isoproterenol (ISO)-induced heart failure models, Pharm. Res, 176, 10.1016/j.phrs.2022.106077 · DOI
  48. Chen, 2019, Role of TLR4/NADPH oxidase 4 pathway in promoting cell death through autophagy and ferroptosis during heart failure, Biochem Biophys. Res Commun., 516, 37, 10.1016/j.bbrc.2019.06.015 · DOI
  49. Wu, 2023, TRIM-containing 44 aggravates cardiac hypertrophy via TLR4/NOX4-induced ferroptosis, J. Mol. Med., 101, 685, 10.1007/s00109-023-02318-3 · DOI
  50. Rhee, 2000, Murine TOLL-like receptor 4 confers lipopolysaccharide responsiveness as determined by activation of NF kappa B and expression of the inducible cyclooxygenase, J. Biol. Chem., 275, 34035, 10.1074/jbc.M007386200 · DOI
  51. del Zoppo, 2000, Inflammation and stroke: putative role for cyto-kines, adhesion molecules and iNOS in brain response to ischemia, Brain Pathol., 10, 95, 10.1111/j.1750-3639.2000.tb00247.x · DOI
  52. Caso, 2007, Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke, Circulation, 115, 1599, 10.1161/CIRCULATIONAHA.106.603431 · DOI
  53. Lehnardt, 2002, The toll-like recep-tor TLR4 is necessary for lipopolysaccharide-induced oligodendrocyte injury in the CNS, J. Neurosci., 22, 2478, 10.1523/JNEUROSCI.22-07-02478.2002 · DOI
  54. Kol, 1998, Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression, Circulation, 98, 300, 10.1161/01.CIR.98.4.300 · DOI
  55. Hopp, 2017, Alleviation of secondary brain injury, post-traumatic inflammation, and brain edema formation by inhibition of factor XIIa., J. Neuroinflamm., 14, 10.1186/s12974-017-0815-8 · DOI
  56. Sinha, 2017, Startle suppression after mild traumatic brain injury is associated with an increase in pro-inflammatory cytokines, reactive gliosis and neuronal loss in the caudal pontine reticular nucleus, Brain Behav. Immun., 61, 353, 10.1016/j.bbi.2017.01.006 · DOI
  57. McKee, 2016, Emerging roles for the immune system in traumatic brain injury, Front Immunol., 7, 556, 10.3389/fimmu.2016.00556 · DOI
  58. Corrigan, 2016, Neurogenic inflammation after traumatic brain injury and its potentiation of classical inflammation, J. Neuroinflamm., 13, 10.1186/s12974-016-0738-9 · DOI
  59. Guadagno, 2015, Microglia-derived IL-1β triggers p53-mediated cell cycle arrest and apoptosis in neural precursor cells, Cell Death Dis., 6, 10.1038/cddis.2015.151 · DOI
  60. Rosa, 2021, TLR4 pathway impairs synaptic number and cerebrovascular functions through astrocyte activation following traumatic brain injury, Br. J. Pharm., 178, 3395, 10.1111/bph.15488 · DOI
  61. Jiang, 2018, Toll-like receptor 4 knockdown attenuates brain damage and neuroin-flammation after traumatic brain injury via inhibiting neuronal autophagy and astrocyte activation, Cell Mol. Neurobiol., 38, 1009, 10.1007/s10571-017-0570-5 · DOI
  62. Chen, 2017, Omega-3 polyunsaturated fatty acid supplementation attenuates microglial-induced inflammation by inhibiting the HMGB1/TLR4/NF-κB pathway following experimental traumatic brain injury, J. Neuroinflamm., 14, 10.1186/s12974-017-0917-3 · DOI
  63. Zhong, 2019, Soluble TREM2 ameliorates pathological pheno-types by modulating microglial functions in an Alzheimer's disease model, Nat. Commun., 10
  64. De Rosa, 2015, Genetics, diagnosis and management of colorectal cancer (Review), Oncol. Rep., 34, 1087, 10.3892/or.2015.4108 · DOI
  65. Singh, 2014, Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis, Immunity, 40, 128, 10.1016/j.immuni.2013.12.007 · DOI · Paper page
  66. Rooks, 2016, Gut microbiota, metabolites and host immunity, Nat. Rev. Immunol., 16, 341, 10.1038/nri.2016.42 · DOI · Paper page
  67. Li, 2019, Gut microbiota-stimulated cathepsin K secretion mediates TLR4-dependent M2 macrophage polarization and promotes tumor metastasis in colorectal cancer, Cell Death Differ., 26, 2447, 10.1038/s41418-019-0312-y · DOI · Paper page
  68. Sheyhidin, 2011, Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma, World J. Gastroenterol., 17, 3745, 10.3748/wjg.v17.i32.3745 · DOI
  69. Rousseau, 2013, Lipopolysaccharide-induced toll-like receptor 4 signaling enhances the migratory ability of human esophageal cancer cells in a selectin-dependent manner, Surgery, 154, 69, 10.1016/j.surg.2013.03.006 · DOI
  70. Santarpia, 2012, Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy, Expert Opin. Ther. Targets, 16, 103, 10.1517/14728222.2011.645805 · DOI
  71. Wu, 2016, Activation of PPARγ suppresses proliferation and induces apoptosis of esophageal cancer cells by inhibiting TLR4-dependent MAPK pathway, Oncotarget, 7, 44572, 10.18632/oncotarget.10067 · DOI
  72. Fels Elliott, 2017, Impact of mutations in Toll-like receptor pathway genes on esophageal carcinogenesis, PLoS Genet, 13, 10.1371/journal.pgen.1006808 · DOI
  73. Seki, 2007, TLR4 enhances TGF-beta signaling and hepatic fibrosis., Nat. Med, 13, 1324, 10.1038/nm1663 · DOI · Paper page
  74. Samuel, 2011, Actomyosin-mediated cellular tension drives increased tissue stiffness and β-catenin activation to induce epidermal hyperplasia and tumor growth, Cancer Cell, 19, 776, 10.1016/j.ccr.2011.05.008 · DOI
  75. Levental, 2009, Matrix crosslinking forces tumor progression by enhancing integrin signaling, Cell, 139, 891, 10.1016/j.cell.2009.10.027 · DOI · Paper page
  76. Duffield, 2005, Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair, J. Clin. Invest, 115, 56, 10.1172/JCI200522675 · DOI · Paper page
  77. Yang, 2020, Increased neutrophil extracellular traps promote metastasis potential of hepatocellular carcinoma via provoking tumorous inflammatory response, J. Hematol. Oncol., 13, 10.1186/s13045-019-0836-0 · DOI
  78. Lu, 2022, Butyrate-producing Eubacterium rectale suppresses lymphomagenesis by alleviating the TNF-induced TLR4/MyD88/NF-κB axis, Cell Host Microbe, 30, 1139, 10.1016/j.chom.2022.07.003 · DOI
  79. Wang, 2013, Toll-like receptor-4 signaling in mantle cell lymphoma: effects on tumor growth and immune evasion, Cancer, 119, 782, 10.1002/cncr.27792 · DOI
  80. Due, 2012, Neuroexcitatory effects of morphine-3-glucuronide are dependent on Toll-like receptor 4 signaling, J. Neuroinflamm., 9, 200, 10.1186/1742-2094-9-200 · DOI
  81. Wang, 2021, Microglial TLR4-induced TAK1 phosphorylation and NLRP3 activation mediates neuroinflammation and contributes to chronic morphine-induced antinociceptive tolerance, Pharm. Res, 165, 10.1016/j.phrs.2021.105482 · DOI
  82. Liu, 2016, Toll-like receptor 4 contributes to chronic itch, alloknesis, and spinal astrocyte activation in male mice, Pain, 157, 806, 10.1097/j.pain.0000000000000439 · DOI
  83. Agalave, 2021, Sex-dependent role of microglia in disulfide high mobility group box 1 protein-mediated mechanical hypersensitivity, Pain, 162, 446, 10.1097/j.pain.0000000000002033 · DOI
  84. Sorge, 2011, Spinal cord Toll-like receptor 4 mediates inflammatory and neuropathic hypersensitivity in male but not female mice, J. Neurosci., 31, 15450, 10.1523/JNEUROSCI.3859-11.2011 · DOI
  85. Su, 2021, Suppression of TLR4-MyD88 signaling pathway attenuated chronic mechanical pain in a rat model of endometriosis, J. Neuroinflamm., 18, 10.1186/s12974-020-02066-y · DOI
  86. Akiyama, 2012, Mouse model of touch-evoked itch (alloknesis), J. Invest Dermatol., 132, 1886, 10.1038/jid.2012.52 · DOI
  87. Chen, 2023, Mechanisms and treatments of neuropathic itch in a mouse model of lymphoma, J. Clin. Invest, 133, 10.1172/JCI160807 · DOI
  88. O'Neill, 2009, Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer, Pharm. Rev., 61, 177, 10.1124/pr.109.001073 · DOI
  89. Neumann, 2010, Rheumatoid arthritis progression mediated by activated synovial fibroblasts, Trends Mol. Med, 16, 458, 10.1016/j.molmed.2010.07.004 · DOI
  90. Kowalski, 2008, Increased respon-siveness to toll-like receptor 4 stimulation in peripheral blood mononuclear cells from patients with recent onset rheuma-toid arthritis, Mediat. Inflamm., 2008, 10.1155/2008/132732 · DOI
  91. Chen, 2013, The role of high mobility group box chromosomal protein 1 in rheumatoid arthritis, Rheumatology, 52, 1739, 10.1093/rheumatology/ket134 · DOI
  92. Campo, 2012, Hyaluronan differently modulates TLR-4 and the inflammatory response in mouse chondrocytes, Biofactors, 38, 69, 10.1002/biof.202 · DOI
  93. Liu, 2014, TLR2 and TLR4 in autoimmune diseases: a comprehensive review, Clin. Rev. Allergy Immunol., 47, 136, 10.1007/s12016-013-8402-y · DOI
  94. Marrakchi, 2011, Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis, N. Engl. J. Med, 365, 620, 10.1056/NEJMoa1013068 · DOI
  95. Shibata, 2017, Toll-like receptor 4 antagonist TAK-242 inhibits autoinflammatory symptoms in DITRA, J. Autoimmun., 80, 28, 10.1016/j.jaut.2017.01.007 · DOI
  96. Lee, 2017, Neutrophil extracellular traps (NETs) in au-toimmune diseases: A comprehensive review, Autoimmun. Rev., 16, 1160, 10.1016/j.autrev.2017.09.012 · DOI
  97. Yang, 2021, Decreased miR-4512 levels in monocytes and macrophages of individuals with systemic Lupus Erythematosus contribute to innate immune activation and neutrsophil NETosis by targeting TLR4 and CXCL2, Front Immunol., 12
  98. Rui, 2021, Olfactory ec-to-mesenchymal stem cell-derived exosomes ameliorate murine Sjögren's syndrome by modulating the function of mye-loid-derived suppressor cells., Cell Mol. Immunol., 18, 440, 10.1038/s41423-020-00587-3 · DOI
  99. Allam, 2021, RAGE and TLR4 differen-tially regulate airway hyperresponsiveness: Implications for COPD., Allergy, 76, 1123, 10.1111/all.14563 · DOI
  100. Di Stefano, 2017, Bronchial inflammation and bacterial load in stable COPD is associated with TLR4 overexpression, Eur. Respir. J., 49, 1602006, 10.1183/13993003.02006-2016 · DOI
  101. Lee, 2003, Reciprocal modulation of Toll-like receptor-4 sig-naling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids, J. Biol. Chem., 278, 37041, 10.1074/jbc.M305213200 · DOI · Paper page
  102. Eberhart, 1994, Up-regulation of cyclooxygenase 2 gene ex-pression in human colorectal adenomas and adenocarcinomas., Gastroenterology, 107, 1183, 10.1016/0016-5085(94)90246-1 · DOI
  103. Di Gioia, 2015, Toll-like receptor co-receptors as master regulators of the immune response, Mol. Immunol., 63, 143, 10.1016/j.molimm.2014.05.008 · DOI
  104. Lucas, 2013, Role of the Toll Like receptor (TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 pathway, Mol. Neurobiol., 48, 190, 10.1007/s12035-013-8425-7 · DOI · Paper page
  105. Oury, 2014, CD36: linking lipids to the NLRP3 inflammasome, atherogenesis and atherothrombosis, Cell Mol. Immunol., 11, 8, 10.1038/cmi.2013.48 · DOI
  106. Boullier, 2006, Minimally oxidized LDL offsets the apoptotic effects of extensively oxidized LDL and free cholesterol in macrophages, Arterioscler. Thromb. Vasc. Biol., 26, 1169, 10.1161/01.ATV.0000210279.97308.9a · DOI
  107. Dowlati, 2010, A meta-analysis of cytokines in major de-pression, Biol. Psychiatry, 67, 446, 10.1016/j.biopsych.2009.09.033 · DOI · Paper page
  108. Franklin, 2018, Depression and sterile inflammation: Essential role of danger associated molecular patterns, Brain Behav. Immun., 72, 2, 10.1016/j.bbi.2017.10.025 · DOI · Paper page
  109. Xu, 2020, Arctigenin protects against depres-sion by inhibiting microglial activation and neuroinflammation via HMGB1/TLR4/NF-κB and TNF-α/TNFR1/NF-κB path-ways., Br. J. Pharm., 177, 5224, 10.1111/bph.15261 · DOI
  110. Guo, 2019, Baicalin ameliorates neuroinflamma-tion-induced depressive-like behavior through inhibition of toll-like receptor 4 expression via the PI3K/AKT/FoxO1 path-way., J. Neuroinflamm., 16, 10.1186/s12974-019-1474-8 · DOI

Cited by

Sorted by citations

Metadata

Authors
Wei, J., Zhang, Y., Li, H., Wang, F., & Yao, S.
Venue
Biomedicine & Pharmacotherapy
Publisher
Elsevier BV
Published
2023-10
Volume
166
Pages
115338
ISSN
0753-3322
Cited by
121
References
9
Language
en
Funders
Hubei Technological Innovation Special Fund (2019ACA167)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review